FDA Tests WEN Conditioner’s MI/MCI Content In Pursuit Of Hair-Loss Answers
This article was originally published in The Rose Sheet
The MI/MCI preservative combination is a suspect being explored by FDA as part of its investigation into reports of hair loss and other adverse effects linked to WEN Cleansing Conditioners. The agency discusses testing it undertook to quantitate the WEN products’ MI/MCI content in a response to concerns raised by Democratic Congressman Frank Pallone of New Jersey.
You may also be interested in...
CFSAN Director Susan Mayne and other high-level FDA officials met with Guthy-Renker and WEN leadership and outside attorneys in September. The substance of the meeting is being kept under wraps, but it shows FDA’s continued involvement in the WEN issue, which drove discussion at the recent Senate HELP Committee hearing on cosmetics.
In a letter to FDA leadership, Sen. Lamar Alexander, R-Tenn., asks the agency to explain its current regulatory authorities over cosmetics and limitations under current law, as well as how it handles adverse-event reports and takes action against non-compliant products. Alexander chairs the Senate HELP Committee and raised concerns at a recent hearing about FDA’s response to WEN.
Senate Health, Education, Labor and Pensions Committee members used the hearing as an opportunity to gain insight into current safety-assurance practices in the cosmetics industry, with national news issues such as WEN and Brazilian Blowout providing the backdrop.